High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction.
OBJECTIVE
We examined whether antibodies against peptides 45 and 210 of apoB-100 are related to myocardial infarction (MI) and severity of coronary atherosclerosis.


RESULTS
Three hundred and eighty-seven survivors of a first MI (aged <60 years) and 387 sex- and age-matched controls were characterized in detail. IgG and IgM autoantibodies against native and malondialdehyde (MDA)-modified peptides 45 and 210 of apoB-100 (amino acids 661-680 and 3136-3155) were quantified in plasma and quantitative coronary angiography was performed in 243 patients. Post-infarction patients had significantly lower IgG against the native peptide 210 (IgG-p210(nat)) and higher IgM against the MDA-modified peptide 210 (IgM-p210(MDA)) compared with controls, whereas no differences were found for other antibodies. Plasma concentrations of IgG-p210(nat), but not IgM-p210(MDA), were independently and inversely related to the degree of coronary atherosclerosis in patients. In multiple logistic regression analysis (including established risk indicators), MI risk was 0.55 (95%CI: 0.37-0.81) for individuals in the IgG-p210(nat) upper quartile compared with the remaining individuals.


CONCLUSIONS
Circulating IgG antibodies against the native peptide 210 of apoB-100 are inversely related to the severity of coronary atherosclerosis and associated with lower risk of MI. Epitope 210 of apoB-100 emerges as a target for immunization against atherosclerosis in humans.
Sjögren
Per
P
Department of Medicine, Atherosclerosis Research Unit, Solna Karolinska Institutet, Stockholm, Sweden. per.sjogren@pubcare.uu.se
Fredrikson
Gunilla N
GN
Samnegard
Ann
A
Ericsson
Carl-Göran
CG
Ohrvik
John
J
Fisher
Rachel M
RM
Nilsson
Jan
J
Hamsten
Anders
A
D053299:Apolipoprotein B-100 / Q000097:blood / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D017023:Coronary Angiography / Q000379:methods; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007075:Immunoglobulin M / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000276:immunology*; D010455:Peptides / Q000097:blood / Q000276:immunology*; D012307:Risk Factors; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
D053299:Apolipoprotein B-100; D001323:Autoantibodies; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D010455:Peptides